Radiotheranostic Agents in Hematological Malignancies

Area of Science:

• Oncology
• Nuclear Medicine
• Immunotherapy

Background:

• Radioimmunotherapy (RIT) combines radiation therapy with monoclonal antibodies (Abs) for cancer treatment.
• Despite early introduction for non-Hodgkin lymphoma, RIT has had limited clinical application.
• Recent advancements focus on theranostic agents using antibody fragments or mimetics for improved tumor targeting.

Purpose of the Study:

• To review strategies for noninvasive detection and treatment of hematological malignancies using radiopharmaceuticals.
• To discuss the evolution and future applications of radiotheranostic agents in personalized medicine.

Main Methods:

• Review of scientific literature on radiopharmaceuticals and theranostic agents.
• Analysis of strategies for improving specificity and pharmacokinetics.
• Discussion of advancements in antibody fragments, peptides, affibodies, and single-chain Abs.

Main Results:

• Development of theranostic agents combining diagnostic and therapeutic capabilities via radionuclide conjugation.
• Trend towards increased specificity, faster pharmacokinetics, and personalized medicine approaches.
• Emergence of novel agents like antibody fragments and small mimetics for enhanced tumor targeting.

Conclusions:

• Radiotheranostic agents represent a significant advancement in treating hematological malignancies.
• Future applications hold promise for more personalized and effective cancer therapies.
• Continued research into novel agents and strategies is crucial for clinical translation.